Hyperspectral Endoscopy Imaging for the Early Detection of Precancerous Lesions in Average Risk Patients
NCT ID: NCT04172493
Last Updated: 2020-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
13 participants
INTERVENTIONAL
2019-08-26
2020-01-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of the Benefit of Chromoendoscopy in Addition to High Definition White Light and Narrow Band Imaging for the Prediction of Submucosal Invasive Cancer in Colonic Lesions
NCT03506321
Detection of Early Gastric Cancers Using Confocal Laser Endomicroscopy
NCT00851305
Measuring the Spectrum of Tissues During Endoscopy
NCT00996619
Application of OE in Diagnosis of EGC
NCT04720521
Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome
NCT03648879
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To assess whether use of hyperspectral endoscopy (HySE) can improve visualization of abnormal colonic tissue.
SECONDARY OBJECTIVES:
I. To assess whether use of HySE could reduce the rate of missed flat polyps.
II. To assess whether use of HySE might in the future reduce the incomplete resection rate (IRR).
III. To examine accuracy of practitioners in predicting polyp histology.
OUTLINE:
Patients undergo standard of care white light endoscopy and hyperspectral endoscopy during routine colonoscopy procedure.
After completion of study, patients who experience a colonoscopy-related severe adverse event are followed up until resolution or stabilization of the event.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DEVICE_FEASIBILITY
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diagnostic
Patients undergo standard of care white light endoscopy (WLE) and hyperspectral endoscopy (HySE) during routine colonoscopy procedure.
Hyperspectral Endoscopy (HySE)
Undergo hyperspectral endoscopy
White Light Endoscopy (WLE)
Undergo white light endoscopy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hyperspectral Endoscopy (HySE)
Undergo hyperspectral endoscopy
White Light Endoscopy (WLE)
Undergo white light endoscopy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients scheduled for a standard of care screening or surveillance colonoscopy
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Oregon Health and Science University
OTHER
OHSU Knight Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vassiliki Tsikitis
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vassiliki L Tsikitis
Role: PRINCIPAL_INVESTIGATOR
OHSU Knight Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
OHSU Knight Cancer Institute
Portland, Oregon, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2019-06087
Identifier Type: REGISTRY
Identifier Source: secondary_id
ONC-19132-L
Identifier Type: -
Identifier Source: secondary_id
STUDY00018947
Identifier Type: OTHER
Identifier Source: secondary_id
STUDY00018947
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.